The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol


ALBAYRAK G., Korkmaz F. D. , Tozcu D., DOĞAN TURAÇLI İ.

JOURNAL OF CELLULAR BIOCHEMISTRY, vol.120, no.6, pp.10564-10571, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 120 Issue: 6
  • Publication Date: 2019
  • Doi Number: 10.1002/jcb.28342
  • Journal Name: JOURNAL OF CELLULAR BIOCHEMISTRY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.10564-10571

Abstract

ObjectivesLung cancer stands out as the most common cancer type worldwide. The most common genetic alteration detected in adenocarcinoma patients is KRAS. KRAS mutated patients still cannot get benefit from precision medicine approaches and lack a targeted therapy. Elesclomol is an investigational agent for melanoma and other malignancies. In this study, we evaluated its effect on cellular apoptosis, survival, and metastasis mechanisms on KRAS mutant A549 and Calu-1 cell lines.